Abstract 246P
Background
First-line (1L) platinum-based chemotherapy (CT) improves survival in metastatic urothelial cancer (mUC). Cisplatin eligibility for pivotal clinical trials excludes renal impairment (eGFR≤60mL/min). Impact of renal impairment on prescribing in the real world is unknown.
Methods
A cohort of mUC patients (pts) having 1L CT was extracted from BLADDA, Australia’s multisite, urothelial cancer registry. Clinicodemographic and outcome data were analysed using descriptive statistics. Statistical significance was defined by p≤0.05. Progression-free (PFS) and overall (OS) survival was defined as time to progression or death from 1L CT.
Results
Our cohort included 132 pts, median age 70 (range 29-86), predominantly male (76%), ECOG 0-1 (88%) and de novo metastatic (58%). Renal function was known in 104 pts; 47% had eGFR≤60 (eGFR 40-60: 34%; eGFR≤40: 13%). Most pts received 1L platinum-based CT (76%). In pts without renal impairment (eGFR>60), carboplatin/gemcitabine was more common than cisplatin/gemcitabine (GC) (40% vs 31%, p=0.3). In pts with renal impairment (eGFR ≤60), carboplatin/gemcitabine remained the most common (33%), followed by GC (18%) and split dose GC (18%). Renal function did not predict cisplatin use (>60: 38% vs ≤60: 37%; OR 1.1, p=0.9), nor impact trial enrolment (>60: 6% vs ≤60: 12%; OR 0.4, p=0.2). Dose reductions were numerically more common in renal impairment (>60: 35% vs ≤60: 49%; OR 2, p=0.2). Renal impairment did not impact response rate (>60: 65% vs ≤60: 68%; p=0.8) but resulted in shorter PFS (14 months, 95% CI 9-19 vs 7, 95% CI 6-8) and OS (37 months, 95% CI 29-NE vs 27, 95% CI 22-33). Table: 246P
All patients (n=132) | eGFR known at 1L treatment (n= 104) | |||
>60 (n= 55) (%) | <60 (n =49) | |||
40-60 (n=35) (%) | <40 (n=14) (%) | |||
1L treatment – Cisplatin-based GC GC (split dose) MVAC/ddMVAC Carboplatin/gemcitabineTrialPembrolizumabOther | 47 (36) 33 (25) 10 (8) 4 (3) 50 (38)11 (8)14 (11)10 (8) | 21 (38) 16 (29) 1 (2) 4 (7) 22 (40)3 (6)7 (13)2 (4) | 11 (31) 6 (17) 5 (14) 0 13 (37)6 (17)3 (9)2 (6) | 7 (50) 3 (21) 4 (29) 0 3 (21)001 (7) |
Median PFS– months (95%CI) | 9 (6-11) | 14 (9-19) | 7 (6-8) | 7 (4-9) |
Median OS – months (95%CI) | 28.8 (21-37) | 37 (29-NE) | 29 (13-45) | 24 (23-25) |
Conclusions
In this real-world analysis, pts receiving 1L CT with impaired renal function had inferior PFS and shortened OS, which was not explained by differences in cisplatin use. Our study is limited by few pts with eGFR<40 and did not evaluate those unfit for CT. Further research to determine optimal 1L therapy in this cohort is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca, BMS, Pfizer, Merck.
Disclosure
A.J. Weickhardt: Financial Interests, Personal, Advisory Board: Merck, Ipsen, Pfizer; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Coordinating PI, PCR MIB funding: Merck. P. Gibbs: Financial Interests, Personal, Advisory Board: Merck, Bayer, Amgen, Servier, Haystack Oncology; Financial Interests, Personal, Invited Speaker: MSD. B. Tran: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Astellas, Bayer, BMS, Ipsen, IQVIA, Janssen, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Tolmar, Sanofi Ammunix; Financial Interests, Personal, Invited Speaker: Amgen, Astellas, AstraZeneca, Bayer, BMS, Merck, Pfizer; Financial Interests, Institutional, Research Grant: Amgen, Astellas, AstraZeneca, Bayer, BMS, Genentech, Ipsen, Janssen, Pfizer, MSD; Financial Interests, Personal, Steering Committee Member: CG Oncology, Janssen, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract